Department of Dermatology, Venereology and Leprology, Government Medical College and Hospital, Chandigarh, India.
Dermatol Ther. 2021 Mar;34(2):e14843. doi: 10.1111/dth.14843. Epub 2021 Feb 15.
Verruca vulgaris (VV) acquired through direct contact or autoinoculation of human papilloma virus (HPV). Treatment of VV are challenging as destructive modalities have variable efficacy and recurrence rates. Various immunotherapies attempt to stimulate the cell-mediated host immune response against HPV. We have assessed efficacy of intralesional tuberculin in patients with verruca vulgaris and to see the long term follow-up at 12 months. Forty patients were enrolled in the study. All patients received intralesional tuberculin injections (5 Tuberculin U/mL) in a dose of 0.1 mL/lesion every fortnightly. Patients were followed up for 12 months duration, and response to treatment assessed. Thirty patients (75%) showed complete resolution, 5 (12.5%) patients showed partial response, 3 (7.5%) showed minimal response and 2 (5%) were non-responders. Irrespective of tuberculin sensitivity test response the majority of patients showed grade 3 response. Five (12.5%) patients had a recurrence of lesions. Two had a recurrence on the same site, and three had recurrences over distant sites. Intralesional tuberculin immunotherapy is an effective modality for VV. Immunotherapy of warts is a potential area of research, and exact method and agents are still under investigation.
寻常疣（VV）通过直接接触或人乳头瘤病毒（HPV）的自身接种获得。VV 的治疗具有挑战性，因为破坏方式的疗效和复发率各不相同。各种免疫疗法试图刺激针对 HPV 的细胞介导的宿主免疫反应。我们评估了皮内结核菌素在寻常疣患者中的疗效，并观察了 12 个月时的长期随访结果。研究纳入了 40 名患者。所有患者均接受皮内结核菌素注射（5 结核菌素 U/mL），剂量为每两周每病变 0.1 mL。患者随访 12 个月，评估治疗反应。30 名患者（75%）完全缓解，5 名患者（12.5%）部分缓解，3 名患者（7.5%）轻度缓解，2 名患者（5%）无反应。无论结核菌素敏感性试验的反应如何，大多数患者均表现出 3 级反应。5 名患者（12.5%）出现病变复发。2 例复发于同一部位，3 例复发于远处部位。皮内结核菌素免疫疗法是治疗 VV 的有效方法。疣的免疫疗法是一个潜在的研究领域，确切的方法和药物仍在研究中。
